[Update of the recommendations of good clinical practice for the use of PET in oncology].
Actualisation des recommandations de bonne pratique clinique pour l’utilisation de la TEP en cancérologie.
Oncologie
Oncology
Positron emission tomography
Recommandation
Recommendation
Tomographie par émission de positon
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
12
06
2018
accepted:
19
11
2018
pubmed:
27
1
2019
medline:
8
3
2019
entrez:
27
1
2019
Statut:
ppublish
Résumé
Positron Emission Tomography (PET) is a functional nuclear medicine imaging technique which clinical value in oncology has been demonstrated. PET indications are constantly evolving, thanks to the contribution of research. The use of PET in oncology has been the subject of recommendations according to the Standard-Options-Recommendations methodology from the Fédération Nationale des Centres de Lutte Contre le Cancer in 2002, updated in 2003. However, many scientific works have been published since 2003 and new tracers have also obtained a marketing authorization in France. The objective of this work was therefore to update the recommendations established in 2003. In this context, in collaboration with the Société française de médecine nucléaire, a working group was set up for the development of good clinical practice recommendations under the HAS-INCA methodological label. The present document is issued from a comprehensive review of the literature and rigorous appraisal by a panel of national experts, organ specialists, clinical oncologists, surgeons, and imaging specialists. It is intended to be used as a guide to decision-making for those oncology teams that are able to manage patients in various situations in which the AMM label is not sufficiently precise.
Identifiants
pubmed: 30683308
pii: S0007-4551(19)30018-9
doi: 10.1016/j.bulcan.2019.01.002
pii:
doi:
Types de publication
Journal Article
Practice Guideline
Systematic Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
262-274Informations de copyright
Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.